$Moderna(MRNA.US)

Moderna: Cancer Vaccine Changes the Game — But Don’t Chase the Spike

Moderna’s 177% single-day surge followed a major breakthrough: its personalised mRNA cancer vaccine, intismeran, met the primary endpoint in a Phase 3 melanoma trial with Merck’s Keytruda, reducing recurrence and cancer spread. (Business Insider⁠)

This is a genuine validation of personalised cancer vaccines. Earlier Phase 2b data showed a 49% reduction in recurrence/death risk and 59% reduction in distant metastasis/death over five years. (Merck.com⁠) However, detailed Phase 3 data and overall-survival results are still pending, so regulatory and commercial risks remain.

Fundamentally, Moderna remains loss-making: Q2 revenue was only $100m, with a $800m net loss, although year-end cash guidance improved to $4.7–5.2bn. (Moderna Investors⁠) Valuation has consequently rerated dramatically, while technically the stock is severely extended after the historic gap-up.

Outlook: HOLD — not Buy at this level. Accumulate only after consolidation or a substantial retracement.

Option writers: favour 30–60 DTE cash-secured puts, targeting 15–25 delta, rather than chasing covered calls immediately. For bearish traders, consider 30–45 DTE calls around 15–20 delta, but only with defined risk.

Not financial advice.